vs

Side-by-side financial comparison of AVIENT CORP (AVNT) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $760.6M, roughly 2.0× AVIENT CORP). Steris runs the higher net margin — 12.9% vs 2.2%, a 10.7% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs 1.9%). Steris produced more free cash flow last quarter ($199.5M vs $125.4M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs -4.2%).

Avient Corporation is a global materials solutions company headquartered in Avon Lake, Ohio, United States, employing approximately 9,000 people worldwide. Its products include colorants, advanced composites, functional additives and engineered materials.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

AVNT vs STE — Head-to-Head

Bigger by revenue
STE
STE
2.0× larger
STE
$1.5B
$760.6M
AVNT
Growing faster (revenue YoY)
STE
STE
+7.3% gap
STE
9.2%
1.9%
AVNT
Higher net margin
STE
STE
10.7% more per $
STE
12.9%
2.2%
AVNT
More free cash flow
STE
STE
$74.1M more FCF
STE
$199.5M
$125.4M
AVNT
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
-4.2%
AVNT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
AVNT
AVNT
STE
STE
Revenue
$760.6M
$1.5B
Net Profit
$16.9M
$192.9M
Gross Margin
30.2%
43.8%
Operating Margin
5.2%
18.3%
Net Margin
2.2%
12.9%
Revenue YoY
1.9%
9.2%
Net Profit YoY
-65.0%
11.2%
EPS (diluted)
$0.18
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVNT
AVNT
STE
STE
Q4 25
$760.6M
$1.5B
Q3 25
$806.5M
$1.5B
Q2 25
$866.5M
$1.4B
Q1 25
$826.6M
$1.5B
Q4 24
$746.5M
$1.4B
Q3 24
$815.2M
$1.3B
Q2 24
$849.7M
$1.3B
Q1 24
$829.0M
$1.1B
Net Profit
AVNT
AVNT
STE
STE
Q4 25
$16.9M
$192.9M
Q3 25
$32.6M
$191.9M
Q2 25
$52.6M
$177.4M
Q1 25
$-20.2M
$145.7M
Q4 24
$48.3M
$173.5M
Q3 24
$38.2M
$150.0M
Q2 24
$33.6M
$145.4M
Q1 24
$49.4M
$-1.4M
Gross Margin
AVNT
AVNT
STE
STE
Q4 25
30.2%
43.8%
Q3 25
30.4%
44.2%
Q2 25
32.1%
45.1%
Q1 25
31.8%
43.3%
Q4 24
34.8%
44.5%
Q3 24
32.1%
43.6%
Q2 24
30.3%
44.7%
Q1 24
33.6%
40.2%
Operating Margin
AVNT
AVNT
STE
STE
Q4 25
5.2%
18.3%
Q3 25
8.3%
18.2%
Q2 25
11.1%
17.7%
Q1 25
0.1%
14.6%
Q4 24
11.5%
17.9%
Q3 24
9.5%
16.5%
Q2 24
8.5%
14.5%
Q1 24
11.3%
22.0%
Net Margin
AVNT
AVNT
STE
STE
Q4 25
2.2%
12.9%
Q3 25
4.0%
13.1%
Q2 25
6.1%
12.8%
Q1 25
-2.4%
9.8%
Q4 24
6.5%
12.7%
Q3 24
4.7%
11.3%
Q2 24
4.0%
11.4%
Q1 24
6.0%
-0.1%
EPS (diluted)
AVNT
AVNT
STE
STE
Q4 25
$0.18
$1.96
Q3 25
$0.36
$1.94
Q2 25
$0.57
$1.79
Q1 25
$-0.22
$1.48
Q4 24
$0.53
$1.75
Q3 24
$0.41
$1.51
Q2 24
$0.36
$1.46
Q1 24
$0.54
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVNT
AVNT
STE
STE
Cash + ST InvestmentsLiquidity on hand
$423.7M
Total DebtLower is stronger
$1.9B
$1.9B
Stockholders' EquityBook value
$2.4B
$7.2B
Total Assets
$6.0B
$10.6B
Debt / EquityLower = less leverage
0.81×
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVNT
AVNT
STE
STE
Q4 25
$423.7M
Q3 25
$319.2M
Q2 25
$279.7M
Q1 25
$171.7M
Q4 24
$155.2M
Q3 24
$172.2M
Q2 24
$198.3M
Q1 24
$207.0M
Total Debt
AVNT
AVNT
STE
STE
Q4 25
$1.9B
$1.9B
Q3 25
$2.0B
$1.9B
Q2 25
$2.0B
$1.9B
Q1 25
$2.1B
$1.9B
Q4 24
$2.1B
$2.0B
Q3 24
$2.1B
$2.2B
Q2 24
$2.1B
$2.2B
Q1 24
$2.1B
$3.1B
Stockholders' Equity
AVNT
AVNT
STE
STE
Q4 25
$2.4B
$7.2B
Q3 25
$2.4B
$7.0B
Q2 25
$2.4B
$7.0B
Q1 25
$2.3B
$6.6B
Q4 24
$2.3B
$6.4B
Q3 24
$2.4B
$6.6B
Q2 24
$2.3B
$6.4B
Q1 24
$2.3B
$6.3B
Total Assets
AVNT
AVNT
STE
STE
Q4 25
$6.0B
$10.6B
Q3 25
$6.1B
$10.4B
Q2 25
$6.1B
$10.4B
Q1 25
$5.8B
$10.1B
Q4 24
$5.8B
$10.0B
Q3 24
$6.0B
$10.2B
Q2 24
$5.9B
$10.1B
Q1 24
$5.9B
$11.1B
Debt / Equity
AVNT
AVNT
STE
STE
Q4 25
0.81×
0.27×
Q3 25
0.83×
0.27×
Q2 25
0.86×
0.27×
Q1 25
0.90×
0.29×
Q4 24
0.89×
0.32×
Q3 24
0.88×
0.33×
Q2 24
0.90×
0.35×
Q1 24
0.90×
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVNT
AVNT
STE
STE
Operating Cash FlowLast quarter
$167.8M
$298.2M
Free Cash FlowOCF − Capex
$125.4M
$199.5M
FCF MarginFCF / Revenue
16.5%
13.3%
Capex IntensityCapex / Revenue
5.6%
6.6%
Cash ConversionOCF / Net Profit
9.93×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$195.0M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVNT
AVNT
STE
STE
Q4 25
$167.8M
$298.2M
Q3 25
$72.1M
$287.8M
Q2 25
$112.8M
$420.0M
Q1 25
$-51.1M
$260.8M
Q4 24
$122.6M
$332.8M
Q3 24
$71.1M
$250.7M
Q2 24
$105.9M
$303.7M
Q1 24
$-42.8M
$254.8M
Free Cash Flow
AVNT
AVNT
STE
STE
Q4 25
$125.4M
$199.5M
Q3 25
$47.4M
$201.3M
Q2 25
$85.8M
$326.4M
Q1 25
$-63.6M
$189.9M
Q4 24
$81.5M
$243.6M
Q3 24
$46.1M
$148.8M
Q2 24
$74.5M
$195.7M
Q1 24
$-67.2M
$163.3M
FCF Margin
AVNT
AVNT
STE
STE
Q4 25
16.5%
13.3%
Q3 25
5.9%
13.8%
Q2 25
9.9%
23.5%
Q1 25
-7.7%
12.8%
Q4 24
10.9%
17.8%
Q3 24
5.7%
11.2%
Q2 24
8.8%
15.3%
Q1 24
-8.1%
14.6%
Capex Intensity
AVNT
AVNT
STE
STE
Q4 25
5.6%
6.6%
Q3 25
3.1%
5.9%
Q2 25
3.1%
6.7%
Q1 25
1.5%
4.8%
Q4 24
5.5%
6.5%
Q3 24
3.1%
7.7%
Q2 24
3.7%
8.4%
Q1 24
2.9%
8.2%
Cash Conversion
AVNT
AVNT
STE
STE
Q4 25
9.93×
1.55×
Q3 25
2.21×
1.50×
Q2 25
2.14×
2.37×
Q1 25
1.79×
Q4 24
2.54×
1.92×
Q3 24
1.86×
1.67×
Q2 24
3.15×
2.09×
Q1 24
-0.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVNT
AVNT

Color Additives And Inks$466.0M61%
Specialty Engineered Materials$295.5M39%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons